FDA has approved the first antivenom treatment specifically for a scorpion sting by the Centruroides scorpions in the United States. The new biologic treatment?called Anascorp?was designated an orphan drug and given priority review because adequate treatment did not exist in the United States, according to a consumer update and corresponding news release issued by the agency.
FDA has approved the first antivenom treatment specifically for stings from Centruroides scorpions in the United States. The new biologic treatment called Anascorp was designated an orphan drug and given priority review because adequate treatment did not exist in the United States, according to a consumer update and corresponding news release issued by the agency.
Anascorp is indicated for the treatment of clinical signs of scorpion envenomation.
“Scorpion stings can be life-threatening, especially in infants and children,” said
Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research in the news release.
FDA’s decision on Anascorp’s effectiveness was based on the results of a randomized, double-blind, placebo-controlled trial of 15 children with neurological signs of scorpion stings. The symptoms which can include can include fluid in the lungs, breathing problems, excess saliva, blurred vision, slurred speech, trouble swallowing, abnormal eye movements, and muscle twitching resolved within 4 hours of treatment in the 8 subjects who received Anascorp. Only one of the 7 participants who received the placebo had resolution of symptoms as quickly. In total, safety and efficacy data was collected from 1,534 patients in both open-label and blinded studies, which were led by the University of Arizona.
Anascorp, Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection, is made from the plasma of horses immunized with scorpion venom. Although the manufacturing process for Anascorp includes steps to decrease the chance of allergic reactions and to reduce the risk of transmission of viruses that may be present in the plasma, the drug may cause early or delayed allergic reactions in people sensitive to horse proteins, the statement said.
The most common side effects of Anascorp were vomiting, fever, rash, nausea, itchiness, headache, runny nose, and muscle pain.
Anascorp is licensed to Rare Disease Therapeutics, Franklin, Tenn., distributed by Accredo Health Group, Memphis, Tenn., and manufactured by Instituto Bioclon, S.A. de C.V., of Tlalpan, Mexico, D.F.
According to FDA statements, Jude McNally, the medical science liaison at Rare Disease Therapeutics, said the Tennessee company will market the new drug to any healthcare facility that accepts emergency patients in areas were the bark scorpion is found, including Arizona, and areas of Clark County, Nev., and parts of New Mexico where the bark scorpion has established colonies, he said.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.